Announced Wed, 22 Jul · 16:23 IST
Dr Reddy Q1 FY27: Revenue falls 5.6%, PAT drops 69% on semaglutide provision
Revenue DeclineEbitda Margin CompressionExceptional ItemAuditor Mid Year ChangeResults View source PDF
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.3%1-day move
₹1180.40
prior close
₹1101.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+3.9+4.2+4.4+4.4-2.3-2.6-3.9———————
Up moveDown movePending
AI summary
Dr Reddy Q1FY27 revenue fell 5.6% YoY to Rs 80,705M, up 7.4% QoQ. PAT attributable to equity holders dropped 69% YoY to Rs 4,435M (EPS Rs 5.32 vs Rs 17.04). North America revenues plunged 35% on lower Lenalidomide sales. A Rs 2,397M provision for semaglutide API issue cut margins by about 3%. EBITDA margin compressed to 12.5% from 26.7%. Emerging Markets grew 31%, India 17%, Europe 13%. Net cash surplus Rs 30,568M.
Likely market impact
Weak Q1 hit by Lenalidomide decline and Rs 2,397M semaglutide provision; underlying base business grew double-digits.